Ranbaxy Shares Fall after U.S. Drug Recall
March 10, 2014 3:29 PM EST
Shares in Ranbaxy Laboratories Ltd(RANB.NS) fell as much as 3.8 percent on Monday after the drug maker recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after dosage mix-up was detected.
A Ranbaxy office building is pictured in the northern Indian city of Mohali on 14 May, 2013
Shares in Ranbaxy, India's biggest drugmaker by revenue and majority owned by Japan's Daiichi Sankyo Co Ltd (4568.T), were down 2.9 percent at 9:20 a.m., underperforming a 0.3 percent fall in the Nifty.
Join the Conversation
- Australia Ranks 11th In World Ultra Wealth Report As 175 Aussies Amass $440B In 2013
- New Zealand Assured China-Australia Deal Will Not Affect Demand
- Product Recall: Graco Recalls Baby Strollers in Canada, U.S. Due To Amputation Risks
- Travel Alert: New Delta Air Lines Airbuses Could Be Seen In Australia Soon
- Travel Alert: Frequent Flyer Tie-Up Between Virgin Australia, South African Airways Enhanced
- Apple and Google Engage in Thermonuclear War, New Google Translate Chat App in the Works
- Russia's New Tactical Nuclear Weapons Program Growing Confident Against the US: Talks of World War III
- More Nexus 6 Problems Arise with Android 5.0 Lollipop, Poor Benchmark Results and Other Issues
- HTC One M8 Android 5.0 Lollipop Release Delayed: Other Schedule and Installation Guide